CoChat

ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol

Mathew, Sanjay J., Wilkinson, Samuel T., Altinay, Murat, Asghar-Ali, Ali, Chang, Lee C., Collins, Katherine A., Dale, Roman M., Hu, Bo, Krishnan, Kamini, Kellner, Charles H., Malone, Donald A., Murrough, James W., Ostroff, Robert B., Sanacora, Gerard, Shao, Mingyuan, Anand, Amit · 2019 · Contemporary Clinical Trials
Cited by 54

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side effects. Ketamine has emerged as the first rapid-acting antidepressant and shows robust short-term efficacy in clinical trials, but there are concerns about its long-term safety and efficacy. While response rates are similar between ECT and ketamine in clinical trials, these treatments have never been compared head-to-head in a sufficiently large, well-powered randomized study. Here we describe the study protocol for ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression (ELEKT-D), a non-inferiority, comparative effectiveness trial. Patients with TRD seeking clinical treatment are randomized (1:1) to receive ECT (thrice weekly) or intravenous ketamine (twice weekly) for 3-5 weeks. The primary outcome is the proportion of responders in each group at the end of study visit, as measured by a patient-reported outcome measure (Quick Inventory of Depressive Symptomatology-Self Report). The study is powered such that the non-inferiority margin allows for ketamine to retain 90% of the ECT treatment effect, with a projected sample size of 400 patients (200 per group). Secondary outcomes include remission rates, depression severity, cognitive functioning, quality of life, adverse events, and tolerability. The results of the ELEKT-D study will have important implications for patient choice, clinical practice, and health insurance policies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cct.2018.12.009

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 54

Metadata

Authors
Mathew, S. J., Wilkinson, S. T., Altinay, M., Asghar-Ali, A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., Malone, D. A., Murrough, J. W., Ostroff, R. B., Sanacora, G., Shao, M., & Anand, A.
Venue
Contemporary Clinical Trials
Publisher
Elsevier BV
Published
2019-02
Volume
77
Pages
19-26
ISSN
1551-7144 (ISSN-L)
OpenAlex
W2905184624
Cited by
54
References
22
FWCI
2.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. https://app.cochat.ai/papers/10.1016/j.cct.2018.12.009
The paper
Mathew, S. J., Wilkinson, S. T., Altinay, M., Asghar-Ali, A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., Malone, D. A., Murrough, J. W., Ostroff, R. B., Sanacora, G., Shao, M., & Anand, A. (2019). ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2018.12.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.